Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application.

Claims 1-71 (canceled)

72. (currently amended): A compound comprising a chemically modified or unmodified double-stranded nucleic acid compound 19-23 nucleotides in length,

wherein a first strand of said compound has at least 19 contiguous nucleotides of ~~a~~ nucleotide sequence ~~selected from the group consisting of SEQ ID NOs:17, 23, 25, 27, 29, 31, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 59, 61, 65, 67, 73, and~~ 81, and

wherein a second strand of said compound is 100% complementary to said first strand.

73. (previously presented): The compound of Claim 72, which is blunt-ended or canonical.

74. (previously presented): The compound of Claim 72, comprising at least one chemical modification to a sugar, nucleobase, or internucleoside linkage.

75. (previously presented): The compound of Claim 74, wherein each chemical modification to said sugar is a 2' modification.

76. (previously presented): The compound of Claim 75, wherein each 2' sugar modification is independently selected from the group consisting of 2'-O-(2-methoxyethyl) (2'-MOE), 2'-O-methyl, locked nucleic acid (LNA), and 2'-fluoro.

77. (previously presented): The compound of Claim 76, wherein each 2' sugar modification is a 2'-O-(2-methoxyethyl) (2'-MOE).

78. (previously presented): The compound of Claim 76, wherein each 2' sugar modification is a 2'-O-methyl.

79. (previously presented): The compound of Claim 76, wherein each 2' sugar modification is a 2'-fluoro.

80. (previously presented): The compound of Claim 76, wherein each 2' modification of said sugar results in a bicyclic sugar.

81. (previously presented): The compound of Claim 80, wherein said 2' modification is a locked nucleic acid (LNA).

82. (previously presented): The compound of Claim 74, wherein said chemical modification to said sugar is a 4' thio.

83. (previously presented): The compound of Claim 75, comprising two or more chemically distinct 2' sugar modifications.

84. (previously presented): The compound of Claim 74, comprising at least one internucleoside linkage modification.

85. (previously presented): The compound of Claim 84, comprising mixed phosphorothioate and phosphodiester linkages.

86. (previously presented): The compound of Claim 85, comprising alternating phosphorothioate and phosphodiester internucleoside linkages.

87. (previously presented): The compound of Claim 76, comprising at least one internucleoside linkage modification.

88. (previously presented): The compound of Claim 87, comprising mixed phosphorothioate and phosphodiester linkages.

89. (previously presented): The compound of Claim 88, comprising alternating phosphorothioate and phosphodiester internucleoside linkages.

90. (previously presented): The compound of Claim 72, comprising a conjugate.

91. cancelled

92. (currently amended): The compound of Claim ~~91~~ 73, wherein said compound is canonical.

93. (previously presented): A pharmaceutical composition, comprising said compound of Claim 72 and a pharmaceutically acceptable carrier, diluent, or excipient.

94. (previously presented): A method for treating a condition associated with survivin expression or overexpression, comprising administering to a human an effective amount of said compound of Claim 72.

95. (previously presented): The method of Claim 94, wherein said condition is cancer.

96. (previously presented): The method of Claim 95, wherein said cancer is selected from the group consisting of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, lung cancer, bladder cancer, ovarian cancer, renal cancer, glioblastoma, pancreatic cancer, and non-Hodgkin's lymphoma.